AVEO Pharmaceuticals, Inc. (AVEO) Analysts See $-0.07 EPS

October 13, 2018 - By Linda Rogers

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) LogoInvestors sentiment increased to 2.11 in 2018 Q2. Its up 0.87, from 1.24 in 2018Q1. It improved, as 15 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 32 funds opened positions while 25 raised stakes. 59.55 million shares or 3.24% more from 57.68 million shares in 2018Q1 were reported.
Excalibur Corporation holds 0.02% or 11,000 shares in its portfolio. Gp One Trading L P reported 250,478 shares or 0% of all its holdings. Bluemountain Mgmt Ltd Liability Com has invested 0.01% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Ny State Common Retirement Fund reported 68,800 shares or 0% of all its holdings. Grimes & Com Incorporated has 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 22,600 shares. California Employees Retirement System accumulated 54,959 shares or 0% of the stock. New Leaf Venture Ptnrs Limited Co invested 0.22% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Ra Cap Mngmt Ltd reported 5.06M shares stake. Citigroup has 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Tower Limited Liability (Trc) reported 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). State Street holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 1.56M shares. Nea Mngmt Limited Liability invested 1.88% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Evercore Wealth Mgmt Limited Liability stated it has 0.03% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Bridgeway Management stated it has 346,464 shares. Vanguard Gp Incorporated, a Pennsylvania-based fund reported 4.99M shares.

Since May 8, 2018, it had 62 buys, and 0 selling transactions for $31.32 million activity. Growth Equity Opportunities IV – LLC also bought $591 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Wednesday, May 30. On Wednesday, June 27 BARRIS PETER J bought $404,077 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) or 192,425 shares. $491,745 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by SANDELL SCOTT D. $491,745 worth of stock was bought by Viswanathan Ravi on Wednesday, July 18. On Wednesday, May 30 the insider MOTT DAVID M bought $591. Florence Anthony A. Jr. had bought 236,479 shares worth $503,423.

Analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report $-0.07 EPS on November, 6.They anticipate $0.05 EPS change or 250.00 % from last quarter’s $-0.02 EPS. After having $-0.15 EPS previously, AVEO Pharmaceuticals, Inc.’s analysts see -53.33 % EPS growth. The stock increased 3.85% or $0.1 during the last trading session, reaching $2.7. About 3.16 million shares traded or 23.00% up from the average. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 19.14% since October 13, 2017 and is downtrending. It has underperformed by 34.76% the S&P500.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $423.40 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

More notable recent AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news were published by: Fool.com which released: “Why AVEO Pharmaceuticals, Inc. Stock Perked Up in September” on October 10, 2018, also Seekingalpha.com with their article: “AVEO Pharma continues up move, shares ahead 7%” published on September 26, 2018, Seekingalpha.com published: “AVEO up 9% on start of data analysis from late-stage study of Fotivda in kidney cancer” on October 01, 2018. More interesting news about AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) were released by: Businesswire.com and their article: “AVEO Oncology to Present Updated Interim Results from the Phase 2 Portion of the TiNivo Study of Tivozanib and …” published on October 09, 2018 as well as Nasdaq.com‘s news article titled: “Why AVEO Pharmaceuticals Inc. Rocketed Higher Today” with publication date: September 25, 2018.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: